Please provide your email address to receive an email when new articles are posted on . Patients receiving nintedanib demonstrated slowed function deterioration compared with those receiving placebo.
A subgroup of patients with SSc who exhibit a severe GI phenotype were associated with longer disease duration, ACA positivity, PAH, and worse quality of life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results